Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 15/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 15/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079314 | 0.83 | GABRA2 (0.70) | GABRA2GABRB2PTGS2KMT2AKDM4E | |
| SCHEMBL1437424 | 0.81 | GABRA2 (0.67) | GABRA2GABRB2PTGS2NR1H2KMT2A | |
| SCHEMBL14351005 | 0.80 | GABRA2 (0.76) | GABRA2GABRB2PTGS2KMT2AKDM4E | |
| SCHEMBL4888122 | 0.78 | GABRA2 (0.61) | GABRA2GABRB2PTGS2NR1H2KMT2A | |
| SCHEMBL9894021 | 0.77 | GABRA2 (0.43) | GABRA2GABRB2KDM4E | |
| SCHEMBL1442132 | 0.77 | GABRA2 (0.42) | GABRA2GABRB2KDM4E | |
| SCHEMBL9893870 | 0.76 | KDM4E (0.46) | GABRA2GABRB2PTGS2KMT2AKDM4E | |
| SCHEMBL5150880 | 0.75 | GABRA2 (0.58) | GABRA2GABRB2PTGS2NR1H2KMT2A | |
| SCHEMBL6533838 | 0.74 | GABRA2 (0.72) | GABRA2GABRB2PTGS2 | |
| SCHEMBL5336123 | 0.74 | GABRA2 (0.72) | GABRA2GABRB2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | GABRA2 4293/4885GABRB2 4278/4885PTGS2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.